Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan or Dato-DXd) to treat adults with ...

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Chewy Inc (NYSE:CHWY) shares are trading lower in Monday's after-hours session after the company announces a public offering ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

The S&P 500 advanced 1% on Monday, June 23, 2025, as investors weighed the potential severity and impact of Iran's ...